There is a growing need for efficacious anti-obesity treatments that produce clinically meaningful, sustained weight loss and ultimately reduce the risk of developing associated metabolic comorbidities, such as diabetes, non-alcoholic steatohepatitis (NASH) and cardiovascular disease (CVD). Of particular promise is the array of new pharmacological analogues of the glucagon-like peptide 1 (GLP-1), as well as other incretin-based approaches. As such, … Continue reading The dietary-induced obese (DIO) mouse: A robust platform for the development of anti-obesity pharmacotherapies